Back to Search Start Over

Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the Role of Bcl-6.

Authors :
Pasqualucci, Laura
Bereschenko, Oxana
Niu, Huifeng
Klein, Ulf
Basso, Katia
Guglielmino, Roberta
Cattoretti, Giorgio
Dalla-Favera, Riccardo
Source :
Leukemia & Lymphoma; Nov2003 Supplement 3, Vol. 44, pS5-S12, 8p
Publication Year :
2003

Abstract

Non-Hodgkin's lymphomas (NHL) form a heterogeneous group of diseases, with diffuse large B-cell lymphoma (DLBCL) comprising the largest subgroup. The commonest chromosomal translocations found in DLBCL are those affecting band 3q27. In 35% of DLBCL cases, as well as in a small fraction of follicular lymphomas, the normal transcriptional regulation of Bcl-6 is disrupted by these chromosomal translocations. In addition, about three-quarters of cases of DLBCL display multiple somatic mutations in the 5' non-coding region of Bcl-6, which occur independently of chromosomal translocations and appear to be due to the IgV-associated somatic hypermutation process. Bcl-6 is a 95-kD nuclear phosphoprotein belonging to the BTB/POZ (bric-a-brac, tramtrack, broad complex/ Pox virus zinc finger) zinc finger family of transcription factors. It has been suggested that Bcl-6 is important in the repression of genes involved in the control of lymphocyte activation, differentiation, and apoptosis within the germinal center, and that its down-regulation is necessary for normal B-cells to exit the germinal center. Bcl-6 remains constitutively expressed in a substantial proportion of B-cell lymphomas. Recently, acetylation has been identified as a mode for down-regulating Bcl-6 activity by inhibition of the ability of Bcl-6 to recruit complexes containing histone deacetylases (HDAC). The pharmacologic inhibition of two recently identified deacetylation pathways, HDAC- and silent information regulator (SIR)-2-dependent deacetylation, results in the accumulation of inactive acetylated Bcl-6 and thus in cell cycle arrest and apoptosis in B-cell lymphoma cells. These results reveal a new method of regulating Bcl-6, with the potential for therapeutic exploitation. These studies also indicate a novel mechanism by which acetylation promotes transcription, not only by modifying histones and activating transcriptional activators, but also by inhibiting transcriptional repressors. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10428194
Volume :
44
Database :
Complementary Index
Journal :
Leukemia & Lymphoma
Publication Type :
Academic Journal
Accession number :
11623571
Full Text :
https://doi.org/10.1080/10428190310001621588